Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 7, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $11.00 to $351,591,600,878.11.

Highlighted Stocks Traded by Insiders:

Intercept Pharmaceuticals (ICPT) - FREE Research Report

Duncan Barbara Gayle, who is Chief Financial Officer at Intercept Pharmaceuticals, sold 141 shares at $176.49 on Jan. 7, 2015. Following this transaction, the Chief Financial Officer owned 17,264 shares meaning that the stake was reduced by 0.81% with the 141-share transaction.

Pruzanski Mark, who is CEO & President at Intercept Pharmaceuticals, sold 461 shares at $176.49 on Jan. 7, 2015. Following this transaction, the CEO & President owned 491,032 shares meaning that the stake was reduced by 0.09% with the 461-share transaction.

Shapiro David, who is CMO and EVP - Development at Intercept Pharmaceuticals, sold 664 shares at $172.63 on Jan. 7, 2015. Following this transaction, the CMO and EVP - Development owned 14,648 shares meaning that the stake was reduced by 4.34% with the 664-share transaction.

Regan Daniel Paul, who is Chief Commercial Officer at Intercept Pharmaceuticals, sold 146 shares at $176.49 on Jan. 7, 2015. Following this transaction, the Chief Commercial Officer owned 1,264 shares meaning that the stake was reduced by 10.35% with the 146-share transaction.

The shares most recently traded at $151.99, down $24.50, or 16.12% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 790
  • 12-Week # shares bought: 2,800
  • 12-Week # shares sold: 790
  • 24-Week # shares bought: 2,800
  • 24-Week # shares sold: 3,997

The average volume for Intercept Pharmaceuticals has been 603,400 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $3.4 billion and is part of the health care sector and drugs industry. Shares are up 0.83% year-to-date as of the close of trading on Wednesday.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Currently, there are 8 analysts who rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Krispy Kreme Doughnuts (KKD) - FREE Research Report

West Togo D Jr, who is Director at Krispy Kreme Doughnuts, sold 6,451 shares at $19.18 on Jan. 7, 2015. Following this transaction, the Director owned 58,002 shares meaning that the stake was reduced by 10.01% with the 6,451-share transaction.

The shares most recently traded at $19.88, up $0.70, or 3.51% since the insider transaction. Historical insider transactions for Krispy Kreme Doughnuts go as follows:

  • 4-Week # shares bought: 450
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 450
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 450
  • 24-Week # shares sold: 4,000

The average volume for Krispy Kreme Doughnuts has been 618,800 shares per day over the past 30 days. Krispy Kreme Doughnuts has a market cap of $1.2 billion and is part of the services sector and leisure industry. Shares are down 0.51% year-to-date as of the close of trading on Wednesday.

Krispy Kreme Doughnuts, Inc., together with its subsidiaries, operates as a branded retailer and wholesaler of doughnuts, beverages, and treats and packaged sweets. The company operates through four segments: Company Stores, Domestic Franchise, International Franchise, and KK Supply Chain. The company has a P/E ratio of 33.8. Currently, there are 3 analysts who rate Krispy Kreme Doughnuts a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KKD - FREE

TheStreet Quant Ratings rates Krispy Kreme Doughnuts as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Krispy Kreme Doughnuts Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Main Street Capital Corporation (MAIN) - FREE Research Report

Jackson John Earl, who is Director at Main Street Capital Corporation, bought 51 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Director owned 11,086 shares meaning that the stake was boosted by 0.46% with the 51-share transaction.

Canon Joseph E, who is Director at Main Street Capital Corporation, bought 369 shares at $30.18 on Jan. 7, 2015. Following this transaction, the Director owned 39,796 shares meaning that the stake was boosted by 0.94% with the 369-share transaction.

Magdol David L., who is Chief Invest. Officer and SMD at Main Street Capital Corporation, bought 403 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Chief Invest. Officer and SMD owned 256,251 shares meaning that the stake was boosted by 0.16% with the 403-share transaction.

Hyzak Dwayne L., who is Coo, Smd at Main Street Capital Corporation, bought 491 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Coo, Smd owned 256,290 shares meaning that the stake was boosted by 0.19% with the 491-share transaction.

Hartman Curtis L., who is Chief Credit Officer and SMD at Main Street Capital Corporation, bought 196 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Chief Credit Officer and SMD owned 197,833 shares meaning that the stake was boosted by 0.1% with the 196-share transaction.

Stout Rodger A., who is Evp at Main Street Capital Corporation, bought 157 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Evp owned 145,411 shares meaning that the stake was boosted by 0.11% with the 157-share transaction.

Appling Michael JR, who is Director at Main Street Capital Corporation, bought 805 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Director owned 89,482 shares meaning that the stake was boosted by 0.91% with the 805-share transaction.

Beauvais Jason B, who is SVP, GC, CCO, Sec. at Main Street Capital Corporation, bought 219 shares at $29.94 on Jan. 7, 2015. Following this transaction, the SVP, GC, CCO, Sec. owned 60,552 shares meaning that the stake was boosted by 0.36% with the 219-share transaction.

Smith Brent D., who is CFO, Treasurer at Main Street Capital Corporation, bought 32 shares at $29.94 on Jan. 7, 2015. Following this transaction, the CFO, Treasurer owned 13,505 shares meaning that the stake was boosted by 0.23% with the 32-share transaction.

Griffin Jon Kevin, who is Director at Main Street Capital Corporation, bought 98 shares at $29.94 on Jan. 7, 2015. Following this transaction, the Director owned 12,571 shares meaning that the stake was boosted by 0.78% with the 98-share transaction.

Martin Shannon, who is VP, Chief Accounting Officer at Main Street Capital Corporation, bought 29 shares at $29.94 on Jan. 7, 2015. Following this transaction, the VP, Chief Accounting Officer owned 16,003 shares meaning that the stake was boosted by 0.18% with the 29-share transaction.

The shares most recently traded at $28.95, down $0.99, or 3.42% since the insider transaction. Historical insider transactions for Main Street Capital Corporation go as follows:

  • 4-Week # shares bought: 2,500
  • 12-Week # shares bought: 2,500
  • 24-Week # shares bought: 3,500

The average volume for Main Street Capital Corporation has been 245,400 shares per day over the past 30 days. Main Street Capital Corporation has a market cap of $1.3 billion and is part of the financial sector and financial services industry. Shares are down 1.44% year-to-date as of the close of trading on Wednesday.

Main Street Capital Corporation is a business development company specializing in long- term equity, equity related, and debt investments in small and lower middle market companies. The stock currently has a dividend yield of 7.2%. The company has a P/E ratio of 12.9. Currently, there are 4 analysts who rate Main Street Capital Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAIN - FREE

TheStreet Quant Ratings rates Main Street Capital Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Main Street Capital Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null